Here's the paradox: cancer is the most preventable of all the chronic illnesses and yet the incidence of cancer growth in Africa and other developing regions of the world is of pandemic proportions, which is exacting a significant economic and social toll.
Reason 1: There is a massive difference between global spend on cancer and on infectious diseases. Although cancer claims more lives globally than HIV/AIDS, malaria and tuberculosis combined, it receives less than three percent of public and private funding from global health. The overwhelming amount goes to infectious diseases.
Reason 2: African countries lack financial clout to attack cancer. They lack epidemiological information to guide resource planning. They lack health workers. They lack the political will and they have competing healthcare demands.
Reason 3: Bad advice. For example, recently a well resourced UK global health advisory group travelled to a poorly resourced African country, which had one of the world's highest rates of cervical cancer mortality and recommended that it should improve its road transport infrastructure to enable health workers easier access to rural areas.
Narrowing the global medical knowledge gap
Sixty years ago, cervical cancer was one of the most common causes of death for western women. However, between 1955 and 1992, the cervical cancer mortality rate in affluent western countries declined by almost 70% as medical knowledge to detect and manage the disease improved. Similar outcomes are true of other forms of cancer to the point where cancer is now preventable and manageable in most developed economies.
According to Margaret Chan, Director General, World Health Organization, the exponential growth of cancer in Africa can be significantly reduced and managed by narrowing the medical knowledge gap between the develop world and African countries.
Notwithstanding, well resourced dedicated centres of global health in affluent developed countries are failing to narrow this gap and thereby failing to reduce and control the 12 million cancer cases that occur annually. If this gap continues over the next 20 years, cancer is expected to exact a significant toll in morbidity, mortality and economic cost particularly in Africa. By 2030, the number of new cancer cases each year is projected to increase to 27 million, cancer deaths to 17 million and much of the cancer burden will fall on poorly resourced African countries.
Mobile phones rather than tarmac
Narrowing the medical knowledge gap between rich and poor countries will neither be achieved by building more roads nor continuing traditional ways of communicating medical knowledge. Such means are slow, costly and ineffective. Narrowing the medical knowledge gap will only be achieved by widespread use of the most ubiquitous healthcare innovation: the mobile telephone.
Although operationally relevant, the mobile telephone is an underdeveloped healthcare application. However, in Africa, the implementation of any healthcare strategy to reduce the burden of cancer and other debilitating health conditions should not be contemplated without leveraging mobile telephony. Why? Because Africa has one of the fastest growing telecommunication infrastructures in the world.
According to a recent joint World Bank and African Development Bank Report there are 650 million mobile users in Africa, surpassing the number in the US and Europe. "In some African countries more people have access to a mobile phone than to clean water, a bank account or electricity," the Report says.
A recent Deloitte's Report suggested that between 2000 and 2012, mobile phone penetration in Africa increased rapidly from one percent to 54%. Today it is over 60%. The main catalyst for this explosive growth is youth. "The cell phone is their landline, ATM and email in one device. Cell phones are central to their life," says Teresa Clarke, CEO, Africa.com.
According to Maurice Nkusi from Namibia Polytechnic who designed a mobile phone-based curriculum, most African youths, "have never even used a computer, but the rapidity with which they master mobile telephony reflects the era in which they live".
Mobile telephony in Africa has narrowed divides between urban and rural, rich and poor and African youth today is the first generation to have direct access to mobile phones, which are used for communicating, transferring money, shopping, listening to the radio and mingling on social media. It is a relatively small step to integrate healthcare content on mobiles that would help prevent and manage cancer.
Africa internet use increases as costs fall
Internet prices in Africa are falling and speed is increasing thanks to fibre-optic submarine cables running along the east and west coasts of Africa and connecting many countries and millions of people.
The Eastern Africa Submarine Cable System (EASSy) is a 10,000km fibre-optic cable deployed along the east and south coast of Africa to service voice, data, video and internet needs of the region. It links South Africa with Sudan via landing points in Mozambique, Madagascar, the Comoros, Tanzania, Kenya, Somalia and Djibouti. The system also interconnects with multiple international submarine cable networks for onward connectivity to Europe, the Americas, the Middle East and Asia.
At a 2013 BRIC summit in South Africa, Andrew Mthembu, chairman, i3 Africa announced that EASSy is to be complimented by a new marine cable connecting 21 African countries with Brazil, Russia and China.
Along the West African coastline is a similar submarine fibre-optic cable, which links West African countries with Europe and brings ultra-fast broadband to a region from Seixal in Portugal through Accra in Ghana to Lagos in Nigeria and branches out in Morocco, Canary Islands, Senegal and Ivory Coast.
This existing 7,000km cable has been recently complemented by a France Telecom-led system, which uses high-speed fibre optic technology to link Europe with 18 countries along the west coast of Africa and provides the capacity to allow approximately 20 million ordinary videos and up to five million high definition videos to be streamed simultaneously, without any buffering.
Today, there are 84 million Internet-enabled mobiles in Africa, all of which can access data and rich media from the internet. By 2014, 69% of mobiles will have Internet access in Africa. In response to the burgeoning demand, African markets are rapidly transitioning from mobiles with limited data access to low-cost smartphones with access to the Internet. Chinese handsets are readily available in Africa for as little as US$20.
Takeaways
Previous HealthPad commentaries have described mHealth initiatives in Africa, but few western centres for global health have fully appreciated that medical knowledge has become mobile, digital and global. Further, they have not fully appreciated the telecommunications revolution that has taken place in Africa over the past decade. Such failures help to explain why the medical knowledge gap between the developed world and African countries has not been narrowed.
This failure is also an opportunity for centres of global health to take a lead in capturing and organising medical knowledge to assist in the management of cancer and other chronic diseases and then to leverage established telecommunications infrastructures to distribute that knowledge to where it is needed the most. What a pity that narrowing the medical knowledge gap was not a Millennium Development Goal.
In 2010, tennis legend Billie Jean King had both her knee joints replaced and it changed her life. Years playing the high-impact sport left the 39-time Grand Slam winner with joint pain and stiffness in her knees. Now at 68, she is playing tennis again. Like Billy Jean, thousands of people are opting to replace their traumatised joints and patients are fast becoming younger.
An escalating incurable and costly condition As populations age peoples' joints are increasingly affected by osteoarthritis, a painful and incurable condition. Dr Anestis Iossifidis consultant orthopaedic surgeon, Croydon University Hospital, UK, says, "Osteoarthritis is the most common disease of the joints and one of the most widespread of all chronic diseases and the most common cause of severe long term pain and physical disability". At any one time, 30% of American adults are affected by joint pain, swelling, or limitation of movement. The prevalence of osteoarthritis increases markedly with age and by 65 can be observed in over half of the American population. Worldwide an estimated 630 million people have their lives blighted by osteoarthritis. In the UK the disease affects about 8.5 million people; a figure set to double to 17 million by 2030. The condition forces 33% of sufferers to retire early and each year this is estimated to cost the UK economy £3.2 billion. |
|
|
Two years ago, Ben Brabyn, a forty year old former British Royal Marine and investment banker turned entrepreneur, visited his doctor with headaches that another doctor had diagnosed as sinusitis. The second doctor suspected a brain tumour and immediately called for an ambulance to take Ben to Charing Cross Hospital, London. Scans showed a fist-sized tumor on the right side of his forehead, see above. Undetected, Ben's tumor could have killed him within days
Any brain tumor is serious and life-threatening because of its invasive nature in the limited space of the intracranial cavity. The threat a brain tumor poses depends on its type, invasiveness, location, size and the state of its development. A tumor may be particularly deadly because it can push against or invade important parts of the brain, as well as cause a lot of swelling that can result in blackouts, fits and other serious health challenges. Within hours of being admitted to hospital, surgeons removed a large panel of bone over Ben's right eye and excised his tumor, which turned out to be a benign meningioma. Most meningiomas are benign and tend to be more common in middle-aged or elderly women than in men. Ben is now fully recovered. Brain tumor deaths are increasing Each year, around 165 million people in Europe are affected by some form of brain-related disorder, which suggests that almost every family in Europe is likely to be affected. Not everyone however will be as lucky as Ben Brabyn. In the US, over 688,000 people are living with primary brain tumors, some 138,000 are malignant and about 550,000 are non-malignant. Since 2004 the incidence of brain tumors in the US has increased by 10%. In 2013 in the US, an estimated 70,000 new cases of primary brain tumors are expected to be diagnosed. In 2012 an estimated 13,700 deaths were attributed to primary brain tumours. Brain tumors are the second-leading cause of cancer deaths in American children. In 2013, approximately 4,300 Americans younger than 20 will be diagnosed with primary brain tumors. In the UK the situation is equally bleak. Over 9,000 people are diagnosed with brain and spinal cord cancer annually and it kills nearly 5,000. Over the past decade there has been a 16% increase in brain tumor deaths. The largest group of primary brain tumors is gliomas; a broad term that includes all tumours arising from the gluey supportive tissue of the brain. These make up 30% of all brain and spinal cord tumors and 80% of malignant brain tumours. |
|
|
|
|
|
|
|
|
|
|
|
|
In January 2013 Andrew Marr, the 53-year-old BBC TV presenter and journalist, had a stroke after a bout of intensive exercise on a rowing machine in a gym. What is a stroke? A stroke is a serious medical emergency where the supply of blood to the brain is disrupted. In over 80% of cases, strokes usually happen because a blood clot blocks the blood supply to the brain. They can also happen when a weakened blood vessel that supplies the brain bursts and causes brain damage, known as a haemorrhagic stroke. Andrew Marr's stroke prompted two questions: (i) Do younger healthy people have strokes? and (ii) Does physical exercise contribute to strokes? Are stroke victims getting younger? Andrew Marr was one of 152,000 people in the UK who have strokes each year. Stroke is the third largest cause of death in the UK and the largest single cause of severe disability. There are approximately 1.1 million stroke survivors living in the UK and each year strokes cost the NHS £2.8 billion. The picture is no better in the US, where every 40 seconds a person has a stroke, each year strokes kill 130,000 and cost the US $38.6. Strokes are uncommon, but not rare in men in their fifties like Andrew Marr. Recent research suggests that strokes among the elderly are declining, while strokes among younger people are increasing. Between 1998 and 1999 in the UK, 9,000 people under 55 were admitted to hospital due to stroke. By 2011 this figure had risen to more than 1,600. It is not altogether clear why stroke is increasing among younger people, although experts note its correlation with type 2 diabetes. The importance of specialist stroke units Andrew Marr said that he believed what he read, that taking, "Very intensive exercise in short bursts is the way to health." Just before his stroke he said, "I went onto a rowing machine and gave it everything I had and had a strange feeling afterwards: a blinding headache and flashes of light". He took no notice and went home. The following morning he woke up lying on the floor unable to move. The most important care for people with any form of stroke is prompt admission to a specialist stroke unit, but even with prompt treatment a stroke can often be fatal. |
|
|
In the UK there are some 2.6 million people living with heart disease, two million more have early signs of it. Each year, roughly 200,000 people die of cardiovascular complications and the disease costs the UK about $10 billion annually. A similar story can be told for most countries. According to the World Health Organisation, "Coronary heart disease is now the leading cause of death worldwide; it is on the rise and has become a true pandemic that respects no borders". A polypill prevents heart attacks and strokes According to a 2012 study undertaken by scientists from the University of London, a polypill that combines three generic blood pressure medicines and a cholesterol fighting drug, reduces blood pressure by 12%, lowers bad cholesterol by 39% and could cut heart disease events by 72% and strokes by 64% and, on average, patients receiving the therapy could gain an extra 11 years of life. According to Dr David Wald from Queen Mary College, London, who led the study, "If half of the over-50s in the UK took the pill daily, it would prevent many thousands of heart attacks and strokes each year". Path breaking gene therapy for heart patients The polypill does not work for chronic heart failure sufferers of which there are more than 0.75 million in the UK alone. Such patients have renewed hope from a new human clinical study, led by Dr Alexander Lyon, Imperial College London, which employs gene therapy to repair damaged hearts. The study is based on 20 years of laboratory research spearheaded by Professor Sian Harding of Imperial College London who discovered that patients suffering from heart failure exhibit low levels of the protein SECRA2a. He also developed a genetically modified virus designed to produce high levels of SECRA2a. Professor Harding then engineered a way for the virus to be introduced into a failing heart to target and reverse some of the critical molecular changes arising in the heart when it fails and thereby restore the diseased organ to its former status. Over a decade ago, gene therapy was widely viewed as a panacea, but it failed to deliver on its early promise. However, recent clinical successes have bolstered renewed optimism in gene therapy and scientists hope that Dr Lyon's study will be a turning point for the technique as well as benefitting people with heart failure. |
|
|
On the 1st November 2006, 43 year old Alexander Litvinenko invited two Russian colleagues for a traditional English afternoon tea at a central London hotel. Litvinenko, a former KBG officer who escaped prosecution in Russia, received political asylum in the UK and became a spy for MI6 as well as the Spanish secret service.
One guest seruptitiously slipped a lethal dose of polonium-210 into Litvinenko's tea. Three weeks later Litvinenko died of radiation poisoning after suffering hair loss, fever, endema, diarrhoea, nausea, vomiting and coma. Today, in thousands of clinics throughout the world, the same radiation that killed Alexander Litvinenko is successfully used to cure or palliate cancer in millions of patients.
Were radiation therapy a drug, it would be a wonder cure.
A booming global device market
Each year worldwide, there are about 13 million new cancer cases diagnosed, about 0.35 million in the UK and some 1.6 million in the US. The National Institute of Health estimates that the annual cost of cancer to the US is about US$227 billion.
About a half of people in the UK and two thirds of Americans diagnosed with cancer receive radiation therapy and radiation oncology has become big business. By 2018 the annual global revenues from the radiation therapy device market are expected to reach US$3.6 billion. Driven by increases in the incidence rate of cancer and increasing demand from emerging markets, the radiation therapy device market is projected to grow at an annual rate of over 9%.
Accuracy with minimal side effects
Radiation therapy employs high energy radiation along a spectrum of different wavelengths. The type and amount of radiation that a patient receives is carefully calculated to destroy cancer cells, while causing as little damage as possible to surrounding healthy tissue. With advances in technology, clinicians are able to give powerful doses of radiation quickly with pinpoint accuracy, targetting only the tumours, sparing nearbly healthy tissue and keeping toxicity levels low. The treatment has minimal side effects.
The genesis
Radiation therapy has its genesis in late 19th century medical experiments undertaken soon after the discovery of X-rays. Twice Nobel Laureatte Marie Curie discovered radium in 1898 and later coined the word "radiation". Radium was used successfully to treat lupus and later was found in hot spring water, which was then marketed as a cure for arthritis, gout and neuralgias.
In the early 20th century, medical science believed that small doses of radiation were harmless and the effects of large doses temporary. Marie Curie was a casualty of this misconception. The widespread use of radium in medicine ended when it was discovered that physical tolerance of radiation was lower than anticipated and exposure resulted in long term cell damage.
In 1934 Marie Curie died of aplastic anemia contracted by excessive exposure to radiation and is buried in a lead-lined coffin. During her life she regularly carried tubes of radioactive isotopes in her pockets and commented on how beautifully they glowed in the dark. Her laboratory is preserved at the Musee Curie, but all her scientific papers are too dangerous to handle and scholars who want access to them have to wear special protective clothing.
Variation in Service
Radiation therapy provision varies significantly across Europe. This is partly because of the financial and technical investments required to establish and operate radiation therapy centres.
In January 2013 The Lancet published a 33 country comparative European study of radiation therapy provision. Researchers found significant disparities in access to radiation treatment, substantial unmet needs and a fair amount of service fragmentation. The Netherlands, Nordic countries and the UK employ a centralized approach, with services concentrated in a few large centres, while in most other European countries the service is more dispersed and facilities vary in size and capacity. The annual number of cancer patients per radiation therapy system ranges from 307 in Switzerland to 1,583 in Romania.
Exquisite accuracy
The late 1990s was a period of progress in radiation therapy with the advent of 3D radiation therapy, intensity-modulated radiation therapy (IMRT) and image guided radiation therapy (IGRT) and today, stereotactic body radiation therapy is widely practiced. This differs from conventional radiation treatment and employs multiple imaging modalities such as PET-CT and MRI, which allows the delivery of high doses of radiation with exquisite accuracy to targeted lesions.
Are healthcare systems and radation therapist ready for the future
Radiation oncology continues to evolve as clinicians and medical scientists climb further up the seed-chain of technology and consider next-generation techniques such as adaptive radiation therapy, which focuses on real-time treatment planning. Recently, the University of Texas, MD Anderson Cancer Center in Houston, US, joined an international research group dedicated to merging radiation therapy and MRI technology, which is expected to deliver images of a patient's soft tissues and tumours during therapy.
The MIMA Cancer Center in Melbourne, Florida, US has invested heavily in radiation therapy and its technological infrastructure. It uses information technology to pull together the interfaces between its treatment planning, treatment delivery and information management systems and provides a repository for images, clinical documentation, scheduling, treatment plans and follow-ups. MIMA is paperless and treatment planning images are immediately sent to treating physicians' image enabled cell phones, which allows them to view images and check data anywhere and at any time. Treating physicians also use their mobile phones to show patients images of their progress.
Such technologies are expected to enhance radiation therapy, but they are also expected to generate petabytes of patient data, increase collaborative and image-dependent workflow and require significant investments in information technology infrastructure.
Are healthcare systems and radiation therapist ready for this?
|
|